Astrazeneca (AZN) Net Margin (2016 - 2026)

Astrazeneca has reported Net Margin over the past 16 years, most recently at 20.15% for Q1 2026.

For Q1 2026, Net Margin fell 942.0% year-over-year to 20.15%; the TTM value through Mar 2026 reached 19.82%, up 145.0%, while the annual FY2025 figure was 17.41%, 74478.0% down from the prior year.
Net Margin for Q1 2026 was 20.15% at Astrazeneca, up from 17.87% in the prior quarter.
Over five years, Net Margin peaked at 29.56% in Q1 2025 and troughed at 3.45% in Q2 2022.
A 5-year average of 15.6% and a median of 15.93% in 2023 define the central range for Net Margin.
On a YoY basis, Net Margin climbed as much as 3558bps in 2022 and fell as far as -1793bps in 2022.
Year by year, Net Margin stood at 15.85% in 2022, then fell by -7bps to 14.81% in 2023, then tumbled by -32bps to 10.07% in 2024, then skyrocketed by 77bps to 17.87% in 2025, then increased by 13bps to 20.15% in 2026.
Business Quant data shows Net Margin for AZN at 20.15% in Q1 2026, 17.87% in Q4 2025, and 16.95% in Q3 2025.

Peer Comparison